Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update
Globe Newswire•28/10/2026•07:00 ET
0
Key Highlights
- ➤TUDRIQEV commercially available for advanced melanoma in the United States
- ➤More than 15 institutions have prescribed TUDRIQEV since its October 6 launch
- ➤Cash and equivalents $307.8 million as of September 30, 2026
- ➤Net loss $57.1 million, narrowing from $83.1 million year over year
- ➤IGNYTE-3 Phase 3 confirmatory study remains actively enrolling on track
Expert Statements
Sushil Patel, Ph.D., CEO of Replimune
“Melanoma takes nearly 8,500 lives in the U.S. every year, and for patients whose disease progresses after anti-PD-1 therapy, treatment options have been limited. TUDRIQEV is now available to patients in urgent need.”
Sushil Patel, Ph.D., CEO of Replimune
“The response from physicians has been enthusiastic and both oncologists and interventional radiologists are eager to bring TUDRIQEV into their practices. They value the broad label that lets them treat patients immediately after progression on a PD-1 based therapy. We are focused on reaching as many of these patients as possible.”
TUDRIQEV first delivered to patients for advanced melanoma on October 6th
WOBURN, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September 30, 2026 and provided a business update.
Get started
Create a free account to read the full story.